This Key Event Relationship is licensed under the Creative Commons BY-SA license. This license allows reusers to distribute, remix, adapt, and build upon the material in any medium or format, so long as attribution is given to the creator. The license allows for commercial use. If you remix, adapt, or build upon the material, you must license the modified material under identical terms.
Relationship: 2399
Title
Bulky DNA adducts, increase leads to Increase, Mutations
Upstream event
Downstream event
AOPs Referencing Relationship
| AOP Name | Adjacency | Weight of Evidence | Quantitative Understanding | Point of Contact | Author Status | OECD Status |
|---|---|---|---|---|---|---|
| Bulky DNA adducts leading to mutations | non-adjacent | Evgeniia Kazymova (send email) | Under development: Not open for comment. Do not cite | Under Development |
Taxonomic Applicability
Sex Applicability
| Sex | Evidence |
|---|---|
| Unspecific |
Life Stage Applicability
| Term | Evidence |
|---|---|
| All life stages |
Bulky DNA adducts occur when aromatic compounds are metabolically activated and interact with DNA bases. Not all of these bulky adductsare stable, however some have been found to persist and cause mutations during repair or replication. The specific mutation that occurs variesby bulky DNA adduct and by chemical. Exposure to the benzo(a)pyrene (B(a)P) or its metabolite anti-benzo(a)pyrene diol epoxide (BPDE)leads to (+/-)-trans-anti-BPDE-N-2-dG adducts, these adducts are associated with G→T transversions (Chiapperino et al. 2002; Zhang et al.2000, 2002), the occurrence of these transversions has been observed both in smokers (Anna et al. 2009; Hainaut and Pfeifer 2001) and in non-smokers (DeMarini et al. 2001). Exposure to aristicholic acid (AA) leads to the persistent DNA adduct 7-(deoxyadenosin-N6-yl) aristolactamI (dA–AAI) adducts and leads to AT→TA transversions (Arlt et al., 2002). Exposure to aflatoxin B1 has been leads to 8,9-dihydro-8- (N7-guanyl)-9-hydroxyaflatoxin B1 (AFB1-N7-Gua) adducts, which can lead to the AFB1-formamidopyrimidine (FAPY) adduct and ultimately causeG→T transversions (Bailey et al. 1996; Smela et al. 2002).
| ID | Experimental Design | Species | Upstream Observation | Downstream Observation | Citation (first author, year) | Notes |
|---|
| Title | First Author | Biological Plausibility |
Dose Concordance |
Temporal Concordance |
Incidence Concordance |
|---|
Biological Plausibility
Dose Concordance Evidence
Temporal Concordance Evidence
Incidence Concordance Evidence
Uncertainties and Inconsistencies
There is some quantitative understanding of the amount of bulky DNA adducts that leads to mutations.
- Broschard et al. 1994 and Broschard, Wiessler, and Schmeiser 1995 found that T7 DNA polymerase and with human DNA polymerase α,respectively, paired dA-AAI equally well with A or T, suggesting that there is a 50% chance of a dA-AAI lesion will lead to a mutation.
- Zhang et al. 2000 found that polymerase eta predominately incorporated A opposite (+)-trans -anti-BPDE-N2-dG bulky adducts, lessfrequently a T was incorporated and least frequently a G or C was incorporated. Suggesting that it is most likely the persistence of a (+)-trans -anti-BPDE-N2 -dG bulky adduct will lead to a mutation of a G to T transversion.
There are also studies demonstrating the quantitative dose-response between bulky DNA adducts and mutations, see Empirical Evidence.
Response-response Relationship
Time-scale
Known Feedforward/Feedback loops influencing this KER
Bulky DNA adducts can occur in any cell type that is able to metabolically activate the stressor. Bulky adducts and resulting mutation frequencyhave been observed in various cell lines in vitro (TK6, HeLa, CHO) as well as various organisms in vivo (yeast, rat, human and mouse). This is unspecific to sex and to life stage.